Objectives To investigate the efficacy and safety of oral semaglutide 7 and 14 mg, the only
orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist tablet approved for type 2 …

Aim To assess the efficacy and safety of oral semaglutide, a novel glucagon‐like peptide‐1
receptor agonist, for patients with type 2 diabetes. Methods We searched Medline, Embase …

Objectives To evaluate the efficacy and safety of the glucagon-like peptide-1 (GLP-1)
receptor agonist (RA) oral semaglutide in the treatment of type 2 diabetes mellitus (T2DM) …

Background: This meta-analysis aimed to combine the data available from clinical trials to
assess the effects of subcutaneous and oral semaglutide administration on glycemic control …

Background and aims Oral semaglutide has undergone global Phase 3 development
programs named PIONEER and approved for therapeutic use in people with type 2 diabetes …

Aims To assess the efficacy and safety of semaglutide, a recently approved glucagon‐like
peptide 1 receptor agonist (GLP‐1 RA) for type 2 diabetes. Materials and methods We …

Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the
treatment of type 2 diabetes and are all currently available as an injection. Objectives To …

Objectives To update and assess the efficacy and tolerability of once weekly subcutaneous
semaglutide in patients with type 2 diabetes (T2D). Materials and methods PubMed, Science …

Objectives To investigate the safety and efficacy of once-weekly glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide as monotherapy or add-on to other …

Background: Semaglutide, a newly once-weekly glucagon like peptide-1 (GLP-1) receptor
agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 …